Intra-Cellular Therapies, Inc. (ITCI)
USD 131.87
(0.0%)
USD 131.87
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -139.67 Million USD | 45.49% |
| 2022 | -256.25 Million USD | 9.81% |
| 2021 | -284.12 Million USD | -25.16% |
| 2020 | -227 Million USD | -53.67% |
| 2019 | -147.72 Million USD | 4.77% |
| 2018 | -155.12 Million USD | -58.66% |
| 2017 | -97.77 Million USD | 16.02% |
| 2016 | -116.42 Million USD | -11.1% |
| 2015 | -104.79 Million USD | -241.44% |
| 2014 | -30.69 Million USD | -14.23% |
| 2013 | -26.86 Million USD | -61.95% |
| 2012 | -16.59 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -15.24 Million USD | 46.65% |
| 2024 Q3 | -26.32 Million USD | -62.29% |
| 2024 Q2 | -16.21 Million USD | -6.38% |
| 2023 Q4 | -28.57 Million USD | -17.81% |
| 2023 FY | -139.67 Million USD | 45.49% |
| 2023 Q1 | -44.05 Million USD | -18.25% |
| 2023 Q2 | -42.78 Million USD | 2.88% |
| 2023 Q3 | -24.25 Million USD | 43.3% |
| 2022 FY | -256.25 Million USD | 9.81% |
| 2022 Q4 | -37.25 Million USD | 30.38% |
| 2022 Q3 | -53.5 Million USD | 36.27% |
| 2022 Q2 | -83.96 Million USD | -16.42% |
| 2022 Q1 | -72.11 Million USD | 15.88% |
| 2021 Q4 | -85.73 Million USD | -11.48% |
| 2021 Q3 | -76.9 Million USD | -11.88% |
| 2021 FY | -284.12 Million USD | -25.16% |
| 2021 Q1 | -52.73 Million USD | 13.11% |
| 2021 Q2 | -68.74 Million USD | -30.34% |
| 2020 Q1 | -47.41 Million USD | -16.82% |
| 2020 FY | -227 Million USD | -53.67% |
| 2020 Q2 | -63.71 Million USD | -34.38% |
| 2020 Q3 | -55.18 Million USD | 13.39% |
| 2020 Q4 | -60.69 Million USD | -9.99% |
| 2019 Q1 | -34.83 Million USD | 14.51% |
| 2019 Q4 | -40.58 Million USD | -16.41% |
| 2019 Q2 | -37.44 Million USD | -7.48% |
| 2019 Q3 | -34.86 Million USD | 6.89% |
| 2019 FY | -147.72 Million USD | 4.77% |
| 2018 Q4 | -40.74 Million USD | 1.87% |
| 2018 FY | -155.12 Million USD | -58.66% |
| 2018 Q3 | -41.52 Million USD | -11.09% |
| 2018 Q2 | -37.37 Million USD | -5.34% |
| 2018 Q1 | -35.48 Million USD | -17.45% |
| 2017 Q3 | -22.87 Million USD | -28.77% |
| 2017 Q2 | -17.76 Million USD | 34.06% |
| 2017 Q1 | -26.93 Million USD | 2.01% |
| 2017 FY | -97.77 Million USD | 16.02% |
| 2017 Q4 | -30.2 Million USD | -32.09% |
| 2016 Q4 | -27.48 Million USD | 9.19% |
| 2016 Q3 | -30.26 Million USD | 1.85% |
| 2016 FY | -116.42 Million USD | -11.1% |
| 2016 Q1 | -27.84 Million USD | 3.44% |
| 2016 Q2 | -30.83 Million USD | -10.75% |
| 2015 Q2 | -21.51 Million USD | 3.48% |
| 2015 FY | -104.79 Million USD | -241.44% |
| 2015 Q4 | -28.83 Million USD | 10.34% |
| 2015 Q3 | -32.16 Million USD | -49.5% |
| 2015 Q1 | -22.28 Million USD | -46.63% |
| 2014 Q4 | -15.19 Million USD | -136.91% |
| 2014 Q2 | -4.53 Million USD | 0.21% |
| 2014 Q3 | -6.41 Million USD | -41.51% |
| 2014 FY | -30.69 Million USD | -14.23% |
| 2014 Q1 | -4.54 Million USD | 43.5% |
| 2013 Q2 | -10.88 Thousand USD | 99.81% |
| 2013 Q3 | -4.91 Million USD | -45031.12% |
| 2013 Q1 | -5.63 Million USD | -386.46% |
| 2013 FY | -26.86 Million USD | -61.95% |
| 2013 Q4 | -8.04 Million USD | -63.71% |
| 2012 Q4 | -1.15 Million USD | 0.0% |
| 2012 FY | -16.59 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 390.051% |
| Embecta Corp. | 70.4 Million USD | 298.401% |
| ANI Pharmaceuticals, Inc. | 18.77 Million USD | 843.778% |
| Dynavax Technologies Corporation | -6.38 Million USD | -2086.164% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 33.25% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 432.914% |
| PainReform Ltd. | -9.34 Million USD | -1394.799% |
| Aquestive Therapeutics, Inc. | -7.87 Million USD | -1674.765% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -2999.703% |
| SCYNEXIS, Inc. | 67.04 Million USD | 308.341% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | -4407.748% |
| Cosmos Health Inc. | -18.54 Million USD | -653.258% |
| Journey Medical Corporation | -3.85 Million USD | -3525.071% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | -2999.703% |
| Safety Shot Inc | -15.08 Million USD | -826.033% |
| Alpha Teknova, Inc. | -36.78 Million USD | -279.755% |
| Bright Green Corporation | -13.12 Million USD | -963.968% |
| Procaps Group, S.A. | 42.54 Million USD | 428.336% |
| Theratechnologies Inc. | -23.95 Million USD | -483.02% |
| Harrow Health, Inc. | -24.41 Million USD | -472.176% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | -2788.811% |
| Biofrontera Inc. | -20.13 Million USD | -593.825% |
| DURECT Corporation | -27.62 Million USD | -405.626% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 10713.526% |
| Cronos Group Inc. | -73.96 Million USD | -88.843% |
| OptiNose, Inc. | -35.48 Million USD | -293.636% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 86.064% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -230.989% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 684.019% |
| Organogenesis Holdings Inc. | 4.94 Million USD | 2924.55% |
| Guardion Health Sciences, Inc. | 158.03 Thousand USD | 88482.806% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | -2124.349% |
| Radius Health, Inc. | -25.79 Million USD | -441.561% |
| Universe Pharmaceuticals INC | -6.16 Million USD | -2166.309% |
| ProPhase Labs, Inc. | -16.78 Million USD | -732.285% |
| Phibro Animal Health Corporation | 2.41 Million USD | 5881.209% |
| Procaps Group S.A. | 42.54 Million USD | 428.336% |
| Alvotech | -551.73 Million USD | 74.684% |
| TherapeuticsMD, Inc. | -10.27 Million USD | -1258.961% |
| Viatris Inc. | 54.7 Million USD | 355.346% |
| Rockwell Medical, Inc. | -8.43 Million USD | -1555.101% |
| Aytu BioPharma, Inc. | -15.84 Million USD | -781.558% |
| SIGA Technologies, Inc. | 68.06 Million USD | 305.195% |
| Tilray Brands, Inc. | -244.98 Million USD | 42.986% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | 1262.69% |
| Shineco, Inc. | -22.44 Million USD | -522.183% |
| PetIQ, Inc. | 2.13 Million USD | 6654.388% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | -3146.845% |
| Incannex Healthcare Limited | -18.45 Million USD | -656.672% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 155.937% |
| Alimera Sciences, Inc. | -20.13 Million USD | -593.791% |
| Silver Spike Investment Corp. | 7.34 Million USD | 2002.888% |
| Assertio Holdings, Inc. | -331.94 Million USD | 57.922% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | -2018.609% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | -1611.023% |
| Clever Leaves Holdings Inc. | -17.89 Million USD | -680.345% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -596.375% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 12.854% |
| Hempacco Co., Inc. | -13.12 Million USD | -964.095% |
| Talphera, Inc. | -18.39 Million USD | -659.222% |
| Alvotech | -551.73 Million USD | 74.684% |
| Eagle Pharmaceuticals, Inc. | 35.64 Million USD | 491.88% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 142.758% |
| Currenc Group, Inc. | -15.3 Million USD | -812.511% |
| Kamada Ltd. | 8.28 Million USD | 1786.07% |
| Indivior PLC | 2 Million USD | 7083.7% |
| Evoke Pharma, Inc. | -7.79 Million USD | -1692.463% |
| Flora Growth Corp. | -57.03 Million USD | -144.887% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | -596.375% |
| Evolus, Inc. | -61.68 Million USD | -126.431% |
| HUTCHMED (China) Limited | 100.78 Million USD | 238.593% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 201.548% |
| Akanda Corp. | -32.27 Million USD | -332.761% |